Article
JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.
Molecular cancer therapeutics - 1 Aug 2017
Kani Kian, Garri Carolina, Tiemann Katrin, Malihi Paymaneh D, Punj Vasu, Nguyen Anthony L, Lee Janet, Hughes Lindsey D, Alvarez Ruth M, Wood Damien M, Joo Ah Young, Katz Jonathan E, Agus David B, Mallick Parag
Abstract excerpt
Mutations or deletions in exons 18-21 in the EGFR) are present in approximately 15% of tumors in patients with non-small cell lung cancer (NSCLC). They lead to activation of the EGFR kinase domain and sensitivity to molecularly targeted therapeutics aimed at this domain (gefitinib or erlotinib). These drugs have demonstrated objective clinical response in many of these patients; however, invariably, all patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.